At a glance
- Originator Sankyo
- Class Antineoplastics; Macrolides; Small molecules
- Mechanism of Action Sphingomyelin phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 08 Feb 2006 No development reported - Preclinical for Inflammation in Japan (PO)
- 31 Aug 1999 New profile
- 31 Aug 1999 Preclinical development for Inflammation in Japan (PO)